Viatris reports FY2024 revenue $14.7B, GAAP net loss $634M, adj EPS $2.65; guides 2025 share buybacks $500-650M

Viatris Inc

2024-FY EPS reported -$0.53 revenue$14,739,300,000

FY2024 total revenues $14.7B; GAAP net loss $634M ($0.53 diluted loss); adjusted EPS $2.65.
Free cash flow $2.0B (incl. ~$650M transaction costs) exceeded guidance; repaid $3.7B debt; leverage 2.9x.
New product revenues $582M; 2025 expects six Phase 3 readouts for selatogrel, cenerimod, sotagliflozin.
2025 guidance includes Indore facility warning letter/import alert impact; enterprise cost review initiated.
Plans $500M-$650M share repurchases in 2025; returned $825M to shareholders in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.